Refine by MP, party, committee, province, or result type.

Results 1-15 of 17
Sorted by relevance | Sort by date: newest first / oldest first

Health committee  I think it's important to keep in mind a couple of things. One is that there are these international agreements that create minimal requirements around intellectual property. You have to have a patent system. You have to put into place, as you say, measures to protect data. But t

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Absolutely, but it's not clear to me that fewer resources means less transparency. I think it might mean the opposite. But specifically, disclosure of clinical study reports—these are things that are provided by the company—if Health Canada is looking at this as something that

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Yes, I do. That was in the paper that Joel, Janice, Elaine, and myself, and Barbara Mintzes published. That was one of the points we thought should be addressed in the bill, simply to make it absolutely plain that other corporate actors in the production chain and distribution

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Thank you for the question. I think it's critical to think about transparency in terms of the institutional picture that Health Canada presents, compared with other regulators. Just thinking about it on its own, it clearly does not necessarily have as many resources as would be

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Absolutely. Bill C-17 is strong as it stands. It could be made really strong if the amendments are included.

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Perhaps I can speak first. I think the point Professor Gibson was making was around restrictive interpretation of harm or injury. Her point was that without clear guidance, harm or injury encompassed products that had been mislabelled or mispackaged and that therefore wouldn't w

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I think there have been other examples where there hasn't been quick action by the regulator because there's been a dispute or a discussion about whether the harm is clearly owing. Diane-35 was another medication that's commonly used to treat acne that has received some attention

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I think it's essential to do a couple of things. One is to ensure that any such conditions placed on a licence to market a drug and to keep doing post-market studies be made publicly known so that others can both hold the company to account and the regulator to account to be foll

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I share the view that it's not clear to me that they are inherently less risky. For that reason, I think they should be regulated very carefully. I think it's more of a strategic consideration in some ways, as my friend just intimated, although I'm not sure it's that difficult to

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  That's a great really specific question. I think the amendments I envision would certainly capture negative results, although I think some very careful thinking would have to be done in defining what a negative result is. I'm trying to capture all results, but if you don't have a

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  That's my view. Under trade agreements, Canada is required to put into place measures to protect data, essentially, which might capture, or some would argue does capture, safety and effectiveness data around a drug. But there are two exceptions to that commitment. One is where i

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I guess I would simply echo that—I thought you were asking specifically about registration as a starter—other kinds of information are critical to get out as well. There's such a course of support for transparency right now that if we limit it to clinical trial registration, whic

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  Clinical trial sites have to receive approval from the government to have a trial conducted there, but they don't necessarily have to comply with any registration requirements. It depends on that site, where it's being conducted in Canada. Publicly funded researchers have to com

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I'm not sure if I quite understand the question. Are you asking with respect to clinical trials as a whole or the information around clinical trials that you thought, by virtue of a commitment to transparency, were asking to be made transparent?

June 10th, 2014Committee meeting

Prof. Matthew Herder

Health committee  I might defer to Joel and Janice for some of the particulars, but what I can say that I think is helpful is that there's been a lot of work to define the particular elements. The World Health Organization has sort of done some work that has led to a minimal set of information to

June 10th, 2014Committee meeting

Prof. Matthew Herder